Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.

Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P.

Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81. Epub 2005 Aug 4.

2.

Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research.

Simmons G, Zmora P, Gierer S, Heurich A, Pöhlmann S.

Antiviral Res. 2013 Dec;100(3):605-14. doi: 10.1016/j.antiviral.2013.09.028. Epub 2013 Oct 8. Review.

3.

SARS coronavirus anti-infectives.

Tong TR.

Recent Pat Antiinfect Drug Discov. 2006 Nov;1(3):297-308. Review.

PMID:
18221155
4.

Recent patents on treatment of severe acute respiratory syndrome (SARS).

Zhai S, Liu W, Yan B.

Recent Pat Antiinfect Drug Discov. 2007 Jan;2(1):1-10. Review.

PMID:
18221160
5.

[Protease-dependent cell entry mechanism of coronaviruses].

Matsuyama S.

Uirusu. 2011 Jun;61(1):109-16. Review. Japanese.

6.

Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies.

Kuhn JH, Li W, Radoshitzky SR, Choe H, Farzan M.

Antivir Ther. 2007;12(4 Pt B):639-50. Review.

PMID:
17944271
7.

Coronaviruses and their therapy.

Haagmans BL, Osterhaus AD.

Antiviral Res. 2006 Sep;71(2-3):397-403. Epub 2006 Jun 19. Review.

PMID:
16837072
8.

Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention.

Yeung KS, Yamanaka GA, Meanwell NA.

Med Res Rev. 2006 Jul;26(4):414-33. Review.

PMID:
16521129
9.

Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections.

Tong TR.

Infect Disord Drug Targets. 2009 Apr;9(2):223-45. Review.

PMID:
19275708
10.

[Antiretroviral drugs in severe acute respiratory syndrome].

Yazdanpanah Y, Guéry B.

Presse Med. 2006 Jan;35(1 Pt 2):105-7. Review. French.

PMID:
16462674
11.

Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirus.

Tan YJ, Lim SG, Hong W.

Antiviral Res. 2006 Nov;72(2):78-88. Epub 2006 Jun 6. Review.

PMID:
16820226
12.

An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.

Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung SH.

J Med Chem. 2016 Jul 28;59(14):6595-628. doi: 10.1021/acs.jmedchem.5b01461. Epub 2016 Feb 29. Review.

PMID:
26878082
13.

Potential antivirals and antiviral strategies against SARS coronavirus infections.

De Clercq E.

Expert Rev Anti Infect Ther. 2006 Apr;4(2):291-302. Review.

PMID:
16597209
14.

Vaccine design for severe acute respiratory syndrome coronavirus.

He Y, Jiang S.

Viral Immunol. 2005;18(2):327-32. Review.

PMID:
16035944
15.

Current status of anti-SARS agents.

Shigeta S, Yamase T.

Antivir Chem Chemother. 2005;16(1):23-31. Review.

PMID:
15739619

Supplemental Content

Support Center